


.....

Working together to  
accelerate patient access  
to advanced therapies

.....



---

# Advanced Therapy Treatment Centre (ATTC) network

---

The ATTC network is a world first, national system of centres operating within the NHS framework and coordinated by the Cell and Gene Therapy Catapult (CGT Catapult) to address the unique and complex challenges of bringing pioneering Advanced Therapy Medicinal Products (ATMPs) to patients.

## The ATTC network includes:

---

Innovate Manchester Advanced Therapy Centre Hub (iMATCH)



---

London Advanced Therapies ATTC



---

Midlands-Wales ATTC



---


Northern Alliance ATTC



# Network impact




Since establishment in 2018, the network has forged close partnerships with the NHS, academia and industry to deliver advanced therapies to patients across the UK.



The UK is an attractive destination for commercial ATMP clinical trials



**9.5%** 

of global trials have representation in the UK

**~80%** 

of trials are conducted by commercial sponsors

# Network activities



The ATTC network coordinates a series of initiatives to increase the attractiveness of the UK to ATMP developers, with a focus on clinical trial delivery. The following case studies exemplify this work and highlight collaborative solutions to shared delivery challenges.



## Formation of the ATTC network Industry Advisory Group

**The Challenge: A driving body is needed to foster collaboration across the ATMP industry to deliver solutions to shared challenges.**

The ATTC network has strengthened the UK's position as a global hub for advanced therapies by accelerating clinical adoption and creating value for industry. Central to this is the Industry Advisory Group (IAG), a forum coordinated by the CGT Catapult, which brings together ATMP developers - from

biotech start-ups to global pharma - to enable the industry to work collaboratively in overcoming shared challenges.

So far, the network has streamlined trial logistics, standardised delivery models, and supported workforce development. These efforts reduce risk for companies, improve trial efficiency, and attract investment - ensuring the UK remains a competitive and innovation-friendly environment for advanced therapy sponsors.

---

## Advanced therapy clinical trials: Barriers and best practice

**The Challenge: The UK is a global leader in advanced therapies, however barriers to timely clinical trial set up and delivery exist which need to be understood and addressed so patients can access these transformative therapies more quickly.**

The network conducted a comprehensive review of complex clinical trials, led by the iMATCH ATTC. This involved designing and distributing a detailed survey, as well as interviewing a broad range of relevant healthcare and industry stakeholders.

The analysis of the findings offered a clear understanding of key barriers and highlighted best practices. Agreed actions to address these barriers and share best practice are now being implemented across the network, helping patients to benefit from accelerated trial start-up in the future.

---

## Commercialisation of an academic CAR-T programme for solid tumours

**The Challenge: While CAR-T therapies have shown great success in certain blood cancers, translating them to effectively treat solid tumours still remains a scientific and clinical hurdle.**

Development of a novel suite of lateral CAR architectures by the CAR Mechanics group at King's College London, a member of the London Advanced Therapies ATTC, led to seed and series A funding of the spin-out company, Leucid Bio.


Leucid Bio is currently conducting a Phase 1 trial of NKG2D-targeted lateral CAR-T therapy (AERIAL), with the first patient globally treated at Guy's Hospital, London in 2025. Learnings and best practice from this trial will be shared through the ATTC network to support accelerated start-up and delivery of future CAR-T trials across the UK.



.....

Through engagement in high-level discussions and by providing expert insights at key industry events, the ATTC network plays a valuable role in shaping decisions that support the delivery of advanced therapies to patients. The following spotlights highlight impactful talks delivered across the network this year.

.....



## Embedding meaningful patient engagement throughout ATMP treatment

At the Advanced Therapies Congress which took place in March 2025 in London, the Midlands-Wales ATTC co-hosted a roundtable discussion on patient engagement. The discussion brought together a diverse group of stakeholders, including clinicians, researchers, commissioners, pharmacists, patient advocates, and industry representatives.

Hosted as part of a broader initiative to centre the patient voice in the development and delivery of ATMPs, the session explored real-world challenges and opportunities in embedding meaningful patient engagement throughout treatment.

Opportunities for enhancing patient equity included:

- Improving appropriate information availability for patients and their support network
- Providing financial and logistical support for patients and families during treatment
- Promoting innovative patient access pathways to make treatments available to patients closer to their home





---

## Highlighting the UK's apheresis capacity at a House of Lords roundtable

The CGT Catapult represented the ATTC network at a House of Lords roundtable in September 2024 hosted by Baroness Ritchie. The roundtable explored the urgent need to expand the UK's apheresis capacity to meet the growing demand from licensed ATMPs and those in clinical trials. Experts from the NHS, industry, and research sectors highlighted current limitations, the impact on patient access and trial delivery.

---

Following the roundtable, a letter was submitted to Baroness Merron, Minister of State for Health, Department of Health and Social Care, detailing the need for coordinated national investment and workforce development to ensure the UK remains competitive in the global cell and gene therapy landscape.

---

## Addressing ATMP training and skills gaps at a Scottish Advanced Therapies Network event

At a March 2025 Scottish Advanced Therapies Network event, coordinated by the CGT Catapult with support from Scottish Enterprise, the Northern Alliance ATTC presented a national programme aimed at addressing critical education and training needs to support ATMP clinical trial delivery. Education and training are critical enablers of the NHS workforce for trial delivery, meeting the needs of patients, trial sponsors, and UK NHS organisations; however, widespread ATMP-specific training and skills gaps exist, which are impacting these trials.

Representatives from across the Scottish ATMP ecosystem gained insight into the importance of NHS preparedness for ATMP clinical research. The presentation highlighted how collaboration between the NHS and other stakeholders, through this national programme, will result in wider patient benefit and support sector growth by attracting new trials across the UK.





Scan here to  
visit our website

Funded by



Innovate  
UK

**NIHR** | National Institute for  
Health and Care Research

Coordinated by

**cATAPULT**  
Cell and Gene Therapy

---

**w** [theattcnetwork.co.uk](http://theattcnetwork.co.uk)

**in** attcnetwork